Marina Ruiz Piñero

Dr. Marina Ruiz Piñero

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2015 in SpringerPlus
Verified
Journal Article
Open access
PDF file
MPMaría Isabel Pedraza
María Isabel Pedraza
CCCarolina de la Cruz
Carolina de la Cruz
MPMarina Ruiz Piñero
Marina Ruiz Piñero
LLLuis López-Mesonero
Luis López-Mesonero
EMElena Martínez
Elena Martínez
AGAngel L L Guerrero
Angel L L Guerrero
OnabotulinumtoxinA (OnabotA) was approved for treatment of chronic migraine (CM) after publication of PREEMPT trials. Thus, we set out to evaluate the efficacy of OnabotA in a series of patients with CM treated according to the PREEMPT protocol.In May 2012 we began to offer OnabotA to patients with CM who did not respond to topiramate and at least one other preventive therapy (beta blocker and/or calcium channel antagonist). We prospectively recorded demographic data and the characteristics of migraine, and we assessed the modifications in monthly headache and migraine days, as well as the number of days of symptomatic medication and triptan intake.By September 2014 we had treated 52 patients (8 male, 44 female), whose age at treatment onset was 42.8 ± 12.7 years (range: 16–71) and age at migraine onset was 16.8 ± 7.8 years (3–32). In 43 of these patients (82.7%) symptomatic overuse of medication was observed at the onset of treatment. A total of 168 procedures were performed and after the first session, we observed a significant reduction in all the variables considered. Twelve (23.1%) patients failed to perceive a positive effect after the first procedure and it was not repeated in 4 of them. By contrast, there was a significant decreasing in all the variables evaluated compared to the baseline in the 39 patients that received a second series of injections.The use of OnabotA according to the PREEMPT paradigm is an effective treatment in patients with chronic migraine in a real-life setting.

23 April 2019 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
RMR. Moreno-Mayordomo
R. Moreno-Mayordomo
MPMarina Ruiz Piñero
Marina Ruiz Piñero
JPJulio Pascual
Julio Pascual
MSM. Gallego de la Sacristana
M. Gallego de la Sacristana
IVI. Vidriales
I. Vidriales
AGAngel L L Guerrero
Angel L L Guerrero
Some variables have been proposed as predictors of efficacy of OnabotulinumtoxinA in chronic migraine patients, but data available are inconclusive. We aimed to analyse the influence of single nucleotide polymorphisms in the response to OnabotulinumtoxinA. We included 156 female patients treated with OnabotulinumtoxinA accordingly to PREEMPT paradigm in three headache units. OnabotulinumtoxinA was offered to patients that had not responded to topiramate and at least one other preventative. Age at first procedure was 43.7 ± 11.8 years (16–74). Patients with a reduction of at least 50% in the number of migraine days after two OnabotulinumtoxinA procedures were considered as responders. We analysed 25 polymorphisms selected for their relevance regarding migraine pathophysiology and their association with migraine according to previously published genome-wide association studies. Genotyping was performed using KASP probes and a LightCycler-480 (Roche-Diagnostics). Allelic, genotypic frequencies and dominance/recesivity hypothesis of the allelic variants were compared between responders and non-responders by Fisher’s exact test. Response to treatment with OnabotulinumtoxinA was achieved in 120 patients (76,9%). Two polymorphisms showed differences: CALCA rs3781719, where allele C represents 26.9% in responders and 40.9% in non-responders (p = 0.007, OR = 3.11 (1.33–7.26)); and TRPV1 rs222749, where allele A represents 4.17% in responders and 12.5% in non-responders (p = 0.013, OR = 3.29 (1.28–8.43)). No significant differences in rest of polymorphisms or clinical or demographic variables were found. Polymorphic variations of CALCA and TRPV1 genes might play a role as prognostic markers of efficacy of OnabotulinumtoxinA in chronic migraine female patients in our population.

25 November 2016 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
PDF file
JBJohanna Barón
Johanna Barón
MPMarina Ruiz Piñero
Marina Ruiz Piñero
MPMaria Palacios-Ceña
Maria Palacios-Ceña
PMPascal Madeleine
Pascal Madeleine
AGAngel L L Guerrero
Angel L L Guerrero
César Fernandez-de-las-PeñasCésar Fernandez-de-las-Peñas
César Fernandez-de-las-Peñas

26 February 2016 in Pain Medicine
Verified
Journal Article
Open access
PDF file
MPMarina Ruiz Piñero
Marina Ruiz Piñero
Jesus Porta EtessamJesus Porta Etessam
Jesus Porta Etessam
SGS. Garcia-Ptacek
S. Garcia-Ptacek
CCC. de la Cruz
C. de la Cruz
MCMaría Luz Cuadrado
María Luz Cuadrado
AGAngel L L Guerrero
Angel L L Guerrero
Background. Auriculotemporal neuralgia (ATN) is an infrequent syndrome consisting in strictly unilateral pain in the temporal region associated with nerve tenderness, which can be successfully treated with anesthetic blockade. We analysed clinical characteristics and treatment response in a series of eight patients. Methods. Series of consecutive patients diagnosed with ATN at Headache Clinics of two university hospitals in Spain. Data on demographic and pain characteristics, as well as response to treatment are presented. Results. Eight patients (seven women). Mean age at onset was 52.8 ± 14.3 years. Pain was strictly unilateral (left-sided in five cases, right-sided in three), and triggered by pressing the preauricular area. Four patients presented background pain, mostly dull in quality, with an intensity of 5.75 ± 1.2 on the verbal analogical scale (VAS). In six, burning exacerbations occurred, ranging from 2 seconds to 30 minutes, with intensity 7.3 ± 1.5 on VAS. Complete relief was achieved with gabapentin in three cases, anaesthetic blockade in three and spontaneously in two. Conclusion. ATN is uncommon in headache units. Gabapentin is a good alternative therapeutic option to anesthetic blockade.

30 April 2015 in The Journal of Headache and Pain
Verified
Journal Article
Open access
PDF file
CRCristina Rodríguez
Cristina Rodríguez
SHSonia Herrero-Velázquez
Sonia Herrero-Velázquez
MPMarina Ruiz Piñero
Marina Ruiz Piñero
JBJohanna Barón
Johanna Barón
ACAlicia Carreres
Alicia Carreres
César Fernandez-de-las-PeñasCésar Fernandez-de-las-Peñas
César Fernandez-de-las-Peñas
Background: Nummular headache (NH) is most commonly a localized unifocal headache; however, some patients infrequently exhibit multifocal symptomatic painful head areas retaining all features of NH. We present the pressure pain sensitivity map of an adolescent with multifocal NH. Case presentation: We describe a case of a 14 year-old-girl with a 3-year history of continuous pain in four rounded areas, all of them with the same size and shape. Pressure pain thresholds (PPT) were assessed on 21 points over the scalp and over the symptomatic areas. A pressure pain sensitivity map of the head was constructed. The neurological exam was unremarkable, with neither sensory symptoms nor trophic changes within the painful areas. As previously shown, symptomatic points exhibited lower PPTs compared to the surrounding areas. The map reflected 4 restricted areas of mechanical hyperalgesia confined just to the painful areas. Treatment with gabapentin achieved complete remission. Conclusion: This is the first pain sensitivity map of a patient with multifocal NH. Our results support peripheral mechanisms are maintained in multifocal NH.

1 April 2015 in Neurología (English Edition)
Verified
Journal Article
Closed access
EREsther García Rojo
Esther García Rojo
MPM.I. Pedraza
M.I. Pedraza
IMI. Muñoz
I. Muñoz
PMPatricia Mulero
Patricia Mulero
MPMarina Ruiz Piñero
Marina Ruiz Piñero
AGAngel L L Guerrero
Angel L L Guerrero